Abbott Denied Stay In Cordis Stent Spat

By Liz McKenzie

Law360 (February 4, 2009, 12:00 AM EST) -- A federal judge has refused to grant Abbott Laboratories’ request to stay an ongoing lawsuit while the U.S. Patent and Trademark Office re-examines four stent patents owned by Johnson & Johnson...

To view the full article, register now.

Try Law360 FREE for seven days

Already a subscriber? Click here to login

Documents

Complaint

Sections

Law Firms

Companies

Government Agencies

Patents

7,217,286 - Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent
7,229,473 - Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent
7,223,286 - Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent
6,585,764 - Stent with therapeutically active dosage of rapamycin coated thereon
6,808,536 - Stent containing rapamycin or its analogs using a modified stent
6,776,796 - Antiinflammatory drug and delivery device
7,300,662 - Drug/drug delivery systems for the prevention and treatment of vascular disease

Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.

Listen To Our Latest